Key Takeaways
- US-China trade tensions escalated over China's rare earth export controls.
- The NBA has resumed operations in China after a six-year absence due to political fallout.
- Chinese surgeons performed a groundbreaking pig-to-human liver transplant, marking a xenotransplantation milestone.
- China's biotech sector is rapidly advancing, poised to disrupt global pharmaceutical markets with innovative and cost-effective solutions.
Deep Dive
- James Kynge identified rare earths as a critical choke point in the US-China superpower rivalry, noting China processes approximately 90% of the world's supply.
- China initially restricted exports of 12 of the 17 known rare earth types, later expanding controls to all rare earths requiring licensing.
- President Trump responded with threats of economic retaliation and canceled a meeting with President Xi, though market stabilization followed de-escalation statements.
- Rare earth minerals are vital for defense, semiconductors, and EVs; the US aims to develop its own domestic supply chain, a process expected to take years.
- Alice Han explained China's export controls are part of a formalized regime, mirroring US actions to gain strategic control over advanced technologies.
- The recent addition of five critical rare earth minerals means all are now subject to licensing, impacting products with minimal Chinese content.
- China's aims are both short-term, to gain leverage in US negotiations, and long-term, to secure its own supply chains, following previous actions like halting soybean imports.
- These controls are timed with efforts to formalize export control frameworks ahead of China's next five-year plan, focused on supply chain securitization.
- The ongoing US-China trade war is viewed as a "divorce neither side can afford," making full economic decoupling an untenable settlement.
- China is adopting US regulatory frameworks, including the Foreign Direct Product Rule (FDPR), mirroring tactics in trade and tech disputes.
- A long-term shift shows China weaponizing its supply chain dominance in critical industries, potentially impacting global manufacturing by 2030 and increasing its leverage against the US.
- This situation is framed as a crucial indicator of future geopolitical dynamics, where China's trading power, after joining the WTO in 2001, could be used for concessions, challenging US superpower status.
- The NBA has returned to China with preseason games between the Brooklyn Nets and Phoenix Suns, the first major league event since the 2019 Hong Kong protests fallout.
- NBA owner Joe Tsai expressed enthusiasm for the team's return, while Chinese legend Yao Ming called it a long-overdue reunion, signifying basketball's importance in China.
- The NBA lost an estimated $300 million due to the 2019 rift; 490 million people watched games between 2018 and 2019.
- The return aligns with Beijing's broader economic strategy to boost domestic consumption in the services sector, with basketball media rights valued at $316 million.
- Chinese surgeons successfully transplanted a genetically modified pig liver into a human patient, who lived for 171 days, with the organ functioning for over a month.
- This xenotransplantation breakthrough is viewed as a potential solution to the global organ shortage, despite ongoing ethical debates and the early stage of the technology.
- Gene editing was crucial to prevent rejection by the human immune system; this procedure follows earlier, less successful attempts, such as a pig lung transplant that lasted nine days.
- The discussion referenced China's controversial 2019 case of gene-edited babies created to be HIV-immune, noting the researcher's return to scientific work.
- Biotech is the strongest performing sector in Chinese markets year-to-date, driven by government investment and its inclusion in national development strategies like 'Made in China 2025.'
- China faces a high incidence of liver failure (300,000 cases annually), positioning xenotransplantation as a significant domestic solution.
- New regulations approved by China's state council create a more lenient approach to biomedical trials, including gene and cell therapies and organ transplants.
- Global licensing of Chinese biotech products has surged over 700% in the last five years, with Morgan Stanley projecting significant revenue growth to $220 billion by 2040.